(Q33396455)

26 July 2017

title

Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma (English)

1 reference

26 July 2017

0 references

1 reference

1 reference

1 reference

S Ahmad

1

0 references

author name string

M Lewis

series ordinal

2

1 reference

26 July 2017

P Corrie

series ordinal

3

1 reference

26 July 2017

M Iddawela

series ordinal

4

1 reference

26 July 2017

publication date

1 August 2011

1 reference

Journal of Oncology Pharmacy Practice

26 July 2017

published in

1 reference

26 July 2017

volume

18

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

287-292

1 reference

Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Current systemic therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Current management of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

Clinical development of the anti-CTLA-4 antibody tremelimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

International consensus report on the investigation and management of primary immune thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1078155211411001

21 January 2018

Identifiers

DOI

10.1177/1078155211411001

1 reference

26 July 2017

1 reference